Des-gamma carboxy prothrombin (PIVKA-II) and alpha-fetoprotein producing gastric cancer with multiple liver metastases

2003 ◽  
Vol 53 (4) ◽  
pp. 236-240 ◽  
Author(s):  
Yoshihisa Takahashi ◽  
Tohru Inoue
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Alpha Fetoprotein ◽  
Multiple Liver Metastases

scholarly journals The Effectiveness of Hepatic Arterial Infusion Chemotherapy with 5-Fluorouracil/Cisplatin and Systemic Chemotherapy with Ramucirumab in Alpha-Fetoprotein-Producing Gastric Cancer with Multiple Liver Metastases

2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Yasuhiro Doi ◽  
Yasushi Takii ◽  
Kenji Mitsugi ◽  
Koichi Kimura ◽  
Yutarou Mihara
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Liver Metastases ◽  
Systemic Chemotherapy ◽  
Hepatic Arterial Infusion ◽  
Alpha Fetoprotein ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Infusion Chemotherapy ◽  
Multiple Liver Metastases

Alpha-fetoprotein- (AFP-) producing gastric cancer (AFPGC) is characterized by a high incidence of liver and lymph node metastases and poor prognosis. Although several case reports have described successful multidisciplinary treatment, there are currently no standard therapies for AFPGC. A 57-year-old man presented with upper abdominal pain. His serum AFP level was extremely high (588.9 ng/mL). Computed tomography (CT) revealed multiple liver metastases with several lesions at an imminent risk of rupture. Five days after admission to our hospital, one lesion ruptured. Transarterial chemoembolization (TACE) of the ruptured tumor was performed, and hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU)/cisplatin (CDDP) to the other liver metastases was administered. The patient’s AFP levels decreased to 297.1 ng/mL. Gastrointestinal endoscopy revealed Borrmann type 2 lesion in the pyloric portion. Pathological examination indicated hepatoid adenocarcinoma of the stomach and metastatic liver. The final diagnosis was AFPGC and multiple liver metastases. The patient underwent systemic chemotherapy with capecitabine/CDDP (cape/CDDP) for three months. His AFP level increased extremely, and CT revealed progression of the liver metastases. TACE was performed, and HAIC (5FU/CDDP) was administered to the progressive lesion of the liver. Originating from the gastric lesion, a distal gastrectomy and D2 + α lymph node resection were performed. One month after the operation, the patient underwent systemic chemotherapy with paclitaxel/ramucirumab (PTX/RAM). After eight cycles of chemotherapy, his AFP level had declined, and CT showed a complete response. After three months of drug withdrawal, the patient has undergone maintenance treatment with RAM. It has been two years since the recurrence. Our experience suggests that HAIC with 5-FU/CDDP and systemic chemotherapy with a regimen including RAM may be an effective treatment for AFPGC.

A case of alpha-fetoprotein-producing gastric cancer in a child presenting with rupture of multiple liver metastases

2015 ◽  
Vol 31 (9) ◽  
pp. 885-888 ◽  
Author(s):  
Eriko Takeyama ◽  
Mio Tanaka ◽  
Jun Fujishiro ◽  
Norihiko Kitagawa ◽  
Tadashi Iwanaka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Alpha Fetoprotein ◽  
Multiple Liver Metastases

scholarly journals Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases

2007 ◽  
Vol 5 (1) ◽  
pp. 79 ◽  
Author(s):  
Hiromitsu Takeyama ◽  
Hirozumi Sawai ◽  
Takehiro Wakasugi ◽  
Hiroki Takahashi ◽  
Yoichi Matsuo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patient ◽  
Liver Metastases ◽  
Gastric Cancer Patient ◽  
Alpha Fetoprotein ◽  
Multiple Liver Metastases

scholarly journals A Case of AFP Producing Gastric Cancer with Multiple Liver Metastases Successfully Treated with Low Dose FAP Via Hepatic Artery

2002 ◽  
Vol 27 (6) ◽  
pp. 902-907
Author(s):  
Toshio TAKAYAMA ◽  
Masahiko SUGANO ◽  
Toshiki KAMANO ◽  
Masahiko TURUMARU ◽  
Yasuo HAYASHIDA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Hepatic Artery ◽  
Low Dose ◽  
Multiple Liver Metastases

scholarly journals Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report

2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Yoichi Hamai ◽  
Jun Hihara ◽  
Manabu Emi ◽  
Yoshiro Aoki ◽  
Kei Kushitani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Case Report ◽  
Liver Metastases ◽  
Sigmoid Colon ◽  
Multiple Liver Metastases

scholarly journals Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment

In Vivo ◽  
2021 ◽  
Vol 35 (5) ◽  
pp. 2929-2935
Author(s):  
TSUTOMU NAMIKAWA ◽  
AKIRA MARUI ◽  
KEIICHIRO YOKOTA ◽  
YUKI FUJIEDA ◽  
MASAYA MUNEKAGE ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Advanced Gastric Cancer ◽  
Combination Treatment ◽  
Conversion Surgery ◽  
Multiple Liver Metastases

What care is appropriate and necessary for metastatic gastric cancer patients? Results of a RAND/UCLA expert panel.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 70-70
Author(s):  
Alyson L. Mahar ◽  
Lucy K. Helyer ◽  
Carol Jane Swallow ◽  
Calvin Law ◽  
Lawrence Frank Paszat ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Surgical Resection ◽  
Metastatic Disease ◽  
Expert Panel ◽  
Treatment Decision ◽  
Metastatic Gastric Cancer ◽  
Treatment Decision Making ◽  
Gastric Cancer Patients ◽  
Multiple Liver Metastases

70 Background: Most gastric cancer patients present with advanced stage disease precluding curative surgical treatment. The utility of surgical and non-surgical options for non-curative, advanced disease is debated and the appropriate treatment strategy unclear. Methods: A multi-disciplinary expert panel of 16 physicians from 6 countries, scored 47 scenarios using the RAND/UCLA Appropriateness Methodology. Appropriateness was scored from 1 (highly inappropriate) to 9 (highly appropriate). Median appropriateness scores (AS) from 1-3 were considered inappropriate, 4-6 uncertain, and 7-9, appropriate. Agreement was reached when 11 of 16 panelists scored the statement similarly. If a statement was agreed to be appropriate, it was then given a necessity score (NS) in the same manner. Results: Surgical resection and bypass were agreed to be inappropriate in patients with minor symptoms and visible carcinomatosis, liver metastases or more than one site of metastatic disease for cardia and distal lesions (AS 1.0-3.5). The expert panel disagreed on the role for surgical resection in patients who were cytology positive only (AS 4-6). The role of resection for patients with major symptoms if they had visible carcinomatosis, liver metastases or more than one site of metastatic disease (AS 2-5) was indeterminate. Patients with distal tumours and major symptoms and multiple liver metastases or more than one site of metastatic disease were considered indeterminate for surgical resection (AS 2). Best supportive care was agreed to be appropriate for patients with minor symptoms and multiple liver metastases or more than one site of metastatic disease (AS 8, NS 5-6). Conclusions: The role of surgery in metastatic gastric cancer treatment decision-making is not supported by experts for the majority of scenarios. Continued uncertainty in appropriate and necessary treatment decision-making for advanced patients with a minimal burden metastatic disease exists and underscores the need for randomized controlled trials.

Sign in / Sign up

Export Citation Format

Share Document